Fundraising FoxBioGenerator Ventures — 2018 Investments
3 investments dated 2018 · listed companies and verified rows first · show all
Euphrates Vascular develops the Pulse NanoMED System, a nanoscale interventional medical device that uses magnetically guided iron-oxide nanoparticles to reach and disrupt distal vascular occlusions beyond the reach of wires and catheters.
BiotechHealthtechMedical DevicesSt. Louis, US
Troy Long(Executive Officer)Jeffrey Blair(Director)Tim Blair(Executive Officer)inEric Moessinger(Director)Robert Mitchell(Director)Thomas Hillman(Director)
Co-investorsAnthro VenturesMissouri Technology CorporationOSF VenturesView Ventures+ND CapitalCultivation Capital
KaloCyte develops ErythroMer, a dried, shelf-stable artificial red blood cell for use in emergency and trauma care when stored blood is unavailable or in short supply.
BiotechDeep TechHealthtechMedical DevicesBaltimore, US
Allan Doctor(Co-Founder & CSO)inDipanjan Pan(Co-Founder, Chief Technical Officer)inPhilip Spinella(Co-Founder, Chief Medical Officer)inDaniel Getman(Director)Gregory Lanza(Director)
Co-investorsBioAdvanceDelaware Crossing Investor GroupMaryland TEDCONYBC VenturesOld Line Capital PartnersTEDCO+1 more
Unleash Immuno Oncolytics is an immuno-oncology company developing armed, conditionally replicating oncolytic viruses that target both tumor cells and the tumor-associated stroma to trigger a systemic anti-cancer immune response.
BiotechLongevitySt. Louis, US
Ariel Muslera(Director)Ricardo Lisandro Bril(Director)Daniel Katzman(Executive Officer, Director)inBolten Charles(Director)
Rows marked “SEC filing” are inferred from directors named on the company's SEC Form D — public regulatory data, not a portfolio list published by the firm.